Spasticity-Pipeline Review, H1 2015

Spasticity-Pipeline Review, H1 2015

  • Products Id :- GMDHC6722IDB
  • |
  • Pages: 85
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Spasticity-Pipeline Review, H1 2015


Global Markets Direct's, 'Spasticity-Pipeline Review, H1 2015', provides an overview of the Spasticity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spasticity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Spasticity

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Spasticity and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Spasticity pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Spasticity

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Spasticity Overview 8

Therapeutics Development 9

Pipeline Products for Spasticity-Overview 9

Pipeline Products for Spasticity-Comparative Analysis 10

Spasticity-Therapeutics under Development by Companies 11

Spasticity-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Spasticity-Products under Development by Companies 15

Spasticity-Companies Involved in Therapeutics Development 16

Addex Therapeutics Ltd 16

Canbex Therapeutics Ltd. 17

Concert Pharmaceuticals, Inc. 18

Daewoong Pharmaceutical Co., Ltd. 19

Echo Pharmaceuticals B.V. 20

GW Pharmaceuticals plc 21

Ipsen S.A. 22

Merz Pharma GmbH & Co. KgaA 23

OBI Pharma, Inc. 24

Osmotica Pharmaceutical Corp. 25

Sanochemia Pharmazeutika AG 26

SciFluor Life Sciences, LLC 27

Sun Pharma Advanced Research Company Ltd. 28

Spasticity-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

abobotulinumtoxin A-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

ADX-71441-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

arbaclofen ER-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

baclofen ER-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CTP-354-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

dronabinol-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

incobotulinumtoxin A-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

nabiximols-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

NB-2221-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

OBI-858-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

onabotulinumtoxin A-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Small Molecule for Spasticity-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

tolperisone-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

VSN-16R-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Spasticity-Recent Pipeline Updates 58

Spasticity-Dormant Projects 71

Spasticity-Discontinued Products 73

Spasticity-Product Development Milestones 74

Featured News & Press Releases 74

Jan 26, 2015: Ipsen announces topline results of two double-blind phase III studies of Dysport in lower limb spasticity in children and in adults 74

Nov 28, 2014: Ipsen Announces FDA Acceptance of Filing for Dysport in the Treatment of Upper Limb Spasticity in Adult Patients 75

Nov 14, 2014: Ipsen Biopharmaceuticals Presents Dysport (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly 76

Oct 13, 2014: Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity 77

Jul 16, 2014: Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity 78

Jul 11, 2014: Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe 78

Apr 12, 2014: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul 79

Dec 17, 2013: Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport in the treatment of Adults suffering from Upper Limb Spasticity 80

Oct 02, 2013: GW Pharmaceuticals Announces New Sativex Data at ECTRIMS 81

Aug 14, 2013: GW Pharmaceuticals Opens an Investigational New Drug Application in the United States for a Sativex Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis 83

Appendix 84

Methodology 84

Coverage 84

Secondary Research 84

Primary Research 84

Expert Panel Validation 84

Contact Us 84

Disclaimer 85

List of Tables

Number of Products under Development for Spasticity, H1 2015 9

Number of Products under Development for Spasticity-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Spasticity-Pipeline by Addex Therapeutics Ltd, H1 2015 16

Spasticity-Pipeline by Canbex Therapeutics Ltd., H1 2015 17

Spasticity-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 18

Spasticity-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 19

Spasticity-Pipeline by Echo Pharmaceuticals B.V., H1 2015 20

Spasticity-Pipeline by GW Pharmaceuticals plc, H1 2015 21

Spasticity-Pipeline by Ipsen S.A., H1 2015 22

Spasticity-Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 23

Spasticity-Pipeline by OBI Pharma, Inc., H1 2015 24

Spasticity-Pipeline by Osmotica Pharmaceutical Corp., H1 2015 25

Spasticity-Pipeline by Sanochemia Pharmazeutika AG, H1 2015 26

Spasticity-Pipeline by SciFluor Life Sciences, LLC, H1 2015 27

Spasticity-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Spasticity Therapeutics-Recent Pipeline Updates, H1 2015 58

Spasticity-Dormant Projects, H1 2015 71

Spasticity-Dormant Projects (Contd..1), H1 2015 72

Spasticity-Discontinued Products, H1 2015 73

List of Figures

Number of Products under Development for Spasticity, H1 2015 9

Number of Products under Development for Spasticity-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Addex Therapeutics Ltd

Canbex Therapeutics Ltd.

Concert Pharmaceuticals, Inc.

Daewoong Pharmaceutical Co., Ltd.

Echo Pharmaceuticals B.V.

GW Pharmaceuticals plc

Ipsen S.A.

Merz Pharma GmbH & Co. KgaA

OBI Pharma, Inc.

Osmotica Pharmaceutical Corp.

Sanochemia Pharmazeutika AG

SciFluor Life Sciences, LLC

Sun Pharma Advanced Research Company Ltd.

Spasticity Therapeutic Products under Development, Key Players in Spasticity Therapeutics, Spasticity Pipeline Overview, Spasticity Pipeline, Spasticity Pipeline Assessment

select a license

Single User License
USD 2000 INR 135980
Site License
USD 4000 INR 271960
Corporate User License
USD 6000 INR 407940



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]